Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 20/20 | 1.00 |
| ▸ | CDK2 | P24941 | 3/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | GSK3B | P49841 | 1/20 | 0.68 |
| ▸ | MARK1 | Q9P0L2 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1369099 | 1.00 | PAK4 (1.00) | PAK4CDK2MAPK1GSK3BMARK1 | |
| Oxirane SCHEMBL3507199 | 0.97 | PAK4 (0.94) | PAK4CDK2MAPK1GSK3BMARK1 | |
| SCHEMBL3503255 | 0.89 | PAK4 (1.00) | PAK4CDK2MAPK1GSK3BMARK1 | |
| SCHEMBL3503256 | 0.89 | PAK4 (1.00) | PAK4CDK2MAPK1GSK3BMARK1 | |
| SCHEMBL1370467 | 0.88 | PAK4 (1.00) | PAK4CDK2MAPK1GSK3BMARK1 | |
| SCHEMBL1370462 | 0.88 | PAK4 (1.00) | PAK4CDK2MAPK1GSK3BMARK1 | |
| SCHEMBL3507193 | 0.88 | PAK4 (1.00) | PAK4CDK2MAPK1GSK3BMARK1 | |
| SCHEMBL13276341 | 0.88 | PAK4 (1.00) | PAK4CDK2MAPK1GSK3BMARK1 | |
| SCHEMBL1940868 | 0.86 | PAK4 (1.00) | PAK4CDK2MAPK1GSK3B | |
| SCHEMBL1369694 | 0.84 | PAK4 (1.00) | PAK4CDK2MAPK1GSK3BMARK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222342-A1 | PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS | ZHANG JUNHU | 2010-09-02 | — | — | US | claimed |
| US-8530652-B2 | Pyrrolopyrazoles, potent kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120264751-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. | 2012-10-18 | — | — | US | disclosed |
| US-8067591-B2 | Pyrrolopyrazole, potent kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| EP-1838718-B1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20100222342-A1 | PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS | ZHANG JUNHU | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264751-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PAK4, PAK5, PAK3 | PAK4 1/4885CDK2 148/4885MAPK1 67/4885 |
| US-20100222342-A1 | PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS | PAK4, PAK5, PAK3 | PAK4 1/4885CDK2 163/4885MAPK1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.